Insider Selling: Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Sells $53,440.00 in Stock

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Gordon Tunstall sold 1,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $53.44, for a total transaction of $53,440.00.

Gordon Tunstall also recently made the following trade(s):

  • On Wednesday, August 21st, Gordon Tunstall sold 10,000 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $65.01, for a total transaction of $650,100.00.
  • On Wednesday, August 14th, Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $62.64, for a total transaction of $62,640.00.
  • On Wednesday, July 10th, Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $52.60, for a total transaction of $52,600.00.
  • On Wednesday, June 19th, Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock. The stock was sold at an average price of $51.52, for a total transaction of $51,520.00.

NASDAQ TRHC opened at $55.25 on Thursday. The firm has a 50-day moving average of $59.36 and a 200-day moving average of $54.07. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.90 and a current ratio of 1.97. The stock has a market cap of $1.26 billion, a PE ratio of 162.50 and a beta of 1.67. Tabula Rasa HealthCare Inc has a 52-week low of $40.86 and a 52-week high of $83.37.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Thursday, August 8th. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.29. The company had revenue of $76.26 million during the quarter, compared to analysts’ expectations of $70.40 million. Tabula Rasa HealthCare had a negative net margin of 7.09% and a positive return on equity of 3.63%. Tabula Rasa HealthCare’s quarterly revenue was up 56.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.20 EPS. As a group, analysts predict that Tabula Rasa HealthCare Inc will post -0.15 EPS for the current fiscal year.

A number of equities analysts have recently issued reports on the stock. BidaskClub lowered shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 4th. TheStreet lowered shares of Tabula Rasa HealthCare from a “c-” rating to a “d+” rating in a report on Tuesday, June 11th. ValuEngine upgraded shares of Tabula Rasa HealthCare from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. Stifel Nicolaus raised shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and increased their price objective for the stock from $50.00 to $75.00 in a research report on Friday, August 30th. Finally, Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “hold” rating to a “strong-buy” rating and set a $72.00 price objective for the company in a research report on Friday, August 16th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and three have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $81.30.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Aperio Group LLC acquired a new stake in shares of Tabula Rasa HealthCare during the 2nd quarter worth about $39,000. First Mercantile Trust Co. lifted its stake in shares of Tabula Rasa HealthCare by 64.5% during the 1st quarter. First Mercantile Trust Co. now owns 995 shares of the company’s stock worth $56,000 after buying an additional 390 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Tabula Rasa HealthCare during the 2nd quarter worth about $82,000. Bank of Montreal Can lifted its stake in shares of Tabula Rasa HealthCare by 167.7% during the 2nd quarter. Bank of Montreal Can now owns 2,605 shares of the company’s stock worth $129,000 after buying an additional 1,632 shares during the last quarter. Finally, Neuburgh Advisers LLC lifted its stake in shares of Tabula Rasa HealthCare by 18.2% during the 2nd quarter. Neuburgh Advisers LLC now owns 2,704 shares of the company’s stock worth $135,000 after buying an additional 416 shares during the last quarter. Institutional investors own 98.75% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Further Reading: What is Blockchain?

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.